Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 27
13 févr. 2018 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference
08 févr. 2018 16h10 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein...
Five Prime Therapeutics Announces Closing of Upsized Public Offering
29 janv. 2018 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) announced today the closing of its upsized public offering of 5,897,435 shares of its...
Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone
25 janv. 2018 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein...
Five Prime Announces Pricing of Upsized Public Offering of Common Stock
25 janv. 2018 08h00 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), announced today the pricing of an underwritten public offering of 5,128,205 shares of its...
Five Prime Announces Proposed Public Offering of Common Stock
23 janv. 2018 16h01 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Collaboration for a Second Time
08 janv. 2018 08h30 HE
|
Five Prime Therapeutics, Inc.
Milestone for antibody targeting TIM-3 triggers $5 million payment to Five Prime BMS extends research collaboration term for discovery, development and commercialization for therapeutics in three...
Five Prime Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
03 janv. 2018 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein...
Five Prime Therapeutics Submits Investigational New Drug Application for Novel B7-H4 Antibody FPA150
03 janv. 2018 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein...
Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric Cancer
02 janv. 2018 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein...